PAYVANDI, FLORA
PAYVANDI, FLORA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Deep Molecular Modeling and Mechanistic Insights into Type 2A VWD with VWF A2 Domain Mutations
2025 O. Seidizadeh, L. Mollica, D. Giana, L. Baronciani, P. Colpani, L. Sicuro, A. Cairo, F. Peyvandi
Global prevalence of platelet-type von Willebrand disease
2025 O. Seidizadeh, A. Cairo, M. Othman, F. Peyvandi
Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
2025 L.P. Solimeno, R. Gualtierotti, E. Guido, J. Acquati Lozej, E. Cristini, A. Ciavarella, S. Arcudi, C. Carulli, L. Pieri, S.M. Siboni, F. Peyvandi
Gene therapy in hemophilia: the dawn of a new era
2025 R. Gualtierotti, A. Giachi, N. Bitto, V. La Mura, F. Peyvandi
Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction
2025 P. Colpani, L. Baronciani, I. Mancini, C. Novembrino, A. Lecchi, G. Cozzi, P. De Leo, M.B. Anzoletti, S. La Marca, M. Boscarino, M.T. Pagliari, A. Artoni, F. Peyvandi
Therapeutic plasma exchange-related complications in patients with immune-mediated thrombotic thrombocytopenic purpura: Complications of therapeutic plasma-exchange
2025 P. Agosti, I. Mancini, A. Artoni, C. Cardone, P. De Leo, C. Bichard, A. Truma, B. Ferrari, J.A. Giannotta, N.N. Fantini, M.C. Mocellin, D. Prati, F. Peyvandi
Inhibitor development in nonsevere hemophilia: data from the European Haemophilia Safety Surveillance (EUHASS) registry
2025 K. Fischer, R. Lassila, F. Peyvandi, A. Gatt, S.C. Gouw, R. Hollingsworth, T. Lambert, R. Kaczmarek, D.C. Alvarez, M. Makris
Clarifying the role of p.Gln723Lys in hTTP prevalence
2025 O. Seidizadeh, A. Cairo, I. Mancini, J.N. George, F. Peyvandi
Challenges and considerations of genetic testing in von Willebrand disease
2025 O. Seidizadeh, L. Baronciani, F. Peyvandi
Genome-wide association study of long COVID
2025 V. Lammi, T. Nakanishi, S.E. Jones, S.J. Andrews, J. Karjalainen, B. Cortes, H.E. O'Brien, A. Ochoa-Guzman, B.E. Fulton-Howard, M. Broberg, H.H. Haapaniemi, M. Kanai, M. Pirinen, A. Schmidt, R.E. Mitchell, A. Mousas, M. Mangino, A. Huerta-Chagoya, N. Sinnott-Armstrong, E.T. Cirulli, M. Vaudel, A.S.F. Kwong, A.K. Maiti, M.M. Marttila, D.C. Posner, A.A. Rodriguez, C. Batini, F. Minnai, A.R. Dearman, C.A.R. Warmerdam, C.B. Sequeros, T.W. Winkler, D.M. Jordan, R. Rescenko, L. Miano, J.M. Lane, R.K. Chung, B. Guillen-Guio, O.C. Leavy, L. Carvajal-Silva, K. Aguilar-Valdes, E. Frangione, L. Guare, E. Vergasova, E. Marouli, P. Striano, U.A. Zainulabid, A. Kumar, H.F. Ahmad, R. Edahiro, S. Azekawa, C. Maj, M.C. Pensel, A. Miller, M.M. Nothen, P. Behzad, S. Schultz, J. Heggemann, D. Balla, D.R. Morrison, V. Mooser, D. Perley, J. Ragoussis, S. Rousseau, F. Shi, G.M. Lathrop, S. Yanishevsky, L. Laurent, D. Auld, M. Bertrand, A. Boisclair, G. Bourque, D. Bujold, M. Durand, D. Adra, J. St-Cyr, M.E.K. Niemi, S.K. Iyengar, T. Cai, K. Cho, S. Sarvadhavabhatla, M.S. Donaire, H. Valenzuela-Jorquera, E. Lamoza, T.V. Arevalo, R. Retamales-Ortega, S. Sanhueza, C.S. Selman, A.X. Silva, T.A. Alarcon, M.F. Martinez, R. Quiroga, P. Zuniga-Pacheco, D. Zapata-Contreras, C.E. Yanez, L.A. Quinones, E.A. Tobar-Calfucoy, V.A. Monardes-Ramirez, I.A. Signore, L.G. Guajardo, A. Figueroa, K.Y. Orostica, C.A. Munoz, M. Fuentes-Guajardo, P. Bocchieri, C. Cabrera, C.A. Echeverria, L.C. Cerpa, G. Donoso, S. Gutierrez-Richards, E. Nova-Lamperti, J.M. Saez Hidalgo, Y. Espinosa-Parrilla, B. Hignell, V. Forgetta, N.R. Harvey, J. Erber, M. Budde, U. Heilbronner, I.-. Larsson, L. Fricke, M. Lipcsey, K. Adorjan, T. Maricic, J.L. Kalman, A. Dinkel, N.S. Mueller, M. Cordioli, U. Protzer, C.D. Spinner, F. Senner, R. Frithiof, E. Wallin, C. Winter, T.G. Schulze, J. Schneider, J. Wiltfang, S. Papiol, C.M. Kripke, A. Verma, M.D. Ritchie, D.J. Rader, L. Trogstad, M. Duran-Gomez, P. Pajukanta, H. Moreno-Macias, S.H.T. Lee, C.A. Aguilar Salinas, G. Castano-Vinyals, M. Kogevinas, X. Farre, A. Carreras, C. Dobano, N. Blay, J. Garcia-Aymerich, A. Blasco, G. Moncunill, S. Iraola-Guzman, R. De Cid, A.L. Guyatt, A.S.B. Mortensen, B. Feenstra, D. Westergaard, S. Brunak, S.R. Ostrowski, N.W. Simons, L.G. Sloofman, A.W. Charney, R.C. Thompson, H. Namkoong, A. Amirsavadkouhi, H.A. Tadi, B. Sharififard, N. Soltani, V. Zarei, R. Aliannejad, E. Ntzani, E. Evangelou, A. Liontos, I. Tzoulaki, H. Milionis, E. Christaki, K.M. Schiabor Barrett, A. Bolze, S. Dabe, I. Neveux, S. White, N.L. Washington, E. Sandoval, F. Tanudjaja, A. Kamelin, V. Ilinsky, D. Kharitonov, A. Kim, N. Plotnikov, L. Shaheen, M. Trofimov, A. Ilinskaya, T. Hannah, F. Colombo, M. Baldassarri, K. Zguro, C. Fallerini, S. Furini, M. Maher, J.M. Cherry, A.C. Burns, R. Saxena, J. Klovins, M. Briviba, P. Raitis, V. Rovite, L.T. Elliott, J. Taher, X. Xinyi, O. Vishnyakova, T.H. Karlsen, F.B.A. Blasi, F. Blandini, A. Bandera, F. Degenhardt, A. Nobili, N. Montano, N. Iannotti, D. Ellinghaus, A. Franke, M. Mantero, G. Lamorte, F. Malvestiti, S. Margarita, A. Muscatello, R. Carpani, F. Peyvandi, D. Prati, L. Ronzoni, M. Tettamanti, A. Kukkonen, S.-. Luoh, C. Erikstrup, O.B.V. Pedersen, J. Lerner-Ellis, A. Colombo, J.J. Grzymski, M. Ishii, Y. Okada, N.D. Beckmann, M. Kumari, R. Wagner, I.M. Heid, C. John, P.J. Short, P. Magnus, L. Ansone, L.V.C. Valenti, S.A. Lee, L.V. Wain, R.A. Verdugo, K. Banasik, F. Geller, L.H. Franke, A. Rakitko, E.L. Duncan, A. Renieri, K.K. Tsilidis, R. De Cid, A. Niavarani, E. Abner, T. Tusie-Luna, S.S. Verma, G.D. Smith, N.J. Timpson, R.K. Madduri, M.J. Daly, A. Ganna, E.C. Schulte, J.B. Richards, K.U. Ludwig, M. Marks-Hultstrom, H. Zeberg, H.M. Ollila
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
2025 K. Fischer, R. Lassila, F. Peyvandi, A. Gatt, S.C. Gouw, R. Hollingsworth, T. Lambert, R. Kaczmarek, D. Carbonero, M. Makris
Adeno-associated virus-based gene therapy for hemophilia–addressing the gaps
2025 W. Miesbach, P. Batty, P. Chowdary, S. Fong, R. Kaczmarek, F.W.G. Leebeek, B. Long, J. Mahlangu, M. Makris, G.F. Pierce, S.W. Pipe, A. Srivastava, J. Voorberg, F. Peyvandi
Operationalising a Haemophilia Gene Editing Lexicon for Practical Use
2025 W. Mckeown, C. Hermans, C. Unzu, M.A. Kay, F. Peyvandi, P. Smith, W. Miesbach, G.F. Pierce, K. Khair, L.A. Valentino, S.W. Pipe, M. Pillai, M. Jones, V. Delwart, A. Sindhurakar, D.E. Gutstein, C.M. Kessler
Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study.
2025 J. Oldenburg, C. Hay, F. Peyvandi, A. Tagliaferri, P.A. Holme, M.T. Álvarez‐román, C. Biron‐andréani, H. Malmström, L. Bystrická, S. Lethagen, N. Null
Design organization and clinical processes around patient characteristics: Evidence from a multiple case study of Hemophilia
2025 S. Villa, R. De Cristofaro, G. Di Minno, S. Laratro, F. Peyvandi, L. Pippo, S. Villa, A.G. De Belvis
Development of a novel gene editing lexicon for hemophilia: methodology and results
2025 C.M. Kessler, L.A. Valentino, C.D. Thornburg, C. Unzu, M.A. Kay, F. Peyvandi, P. Smith, W. Miesbach, W. Mckeown, G.F. Pierce, K. Khair, K. Starcevic, M. Pillai, M. Jones, A. Sindhurakar, L. Whyte, V. Delwart, M. Chiao, D.E. Gutstein, I. Antonino, C. Hermans, S.W. Pipe
Gynecologic and obstetric complications in women with congenital fibrinogen disorders: insights from the Prospective Rare Bleeding Disorders Database
2025 S. Mohsenian, R. Palla, M. Menegatti, A. Cairo, S.M. Siboni, M. Neerman-Arbez, M. Karimi, H. Pargantou, R. Asselta, D. Mikovic, M. Saracevic, B. Laros-van Gorkom, L. Jacobs, A. Shapiro, A. Williamson, M. Makris, A. Casini, F. Peyvandi
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
2025 G. Young, K. Kavakli, R. Klamroth, T. Matsushita, F. Peyvandi, S.W. Pipe, S. Rangarajan, M. Shen, A. Srivastava, J. Sun, H. Tran, C. You, B. Zülfikar, L.A. Menapace, C. Zhang, Y. Shen, M. Puurunen, M. Demissie, G. Kenet
Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe haemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial
2025 L. Malec, M. Mathias, A.L. Dunn, B. Nolan, N. Wong, L. Bystrická, U. Khan, G. Neill, E. Santagostino, S. Gunawardena, C. Tarango, F. Peyvandi
The thrombotic paradox in congenital fibrinogen deficiencies: from pathophysiology to practice
2025 S. Mohsenian, A. Casini, F. Peyvandi